跳至主要内容
临床试验/NCT03156647
NCT03156647已完成不适用

Alpha-synuclein Level in the Saliva as a Potential Diagnostic Aid to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome

Centre Hospitalier Universitaire de Nīmes3 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2017年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80
试验地点
3
主要终点
Compare saliva level of oligomeric alpha-synuclein between two groups of patients wth classical parkinsonian: patients with idiopathic Parkinson disease and patients with a acquired parkinsonian syndrome from anti-dopamine treatment.

研究概览

简要总结

The aim of this study is to determine whether a significant reduction in the total level of alpha-synuclein and significant increase in the oligomeric form of alpha-synuclein and therefore the ratio oligomeric:total alpha-synuclein occurs in patients with Parkinson disease compared to patients with drug-induced parkinsonian syndrome.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • The subject is participating in another study
  • The subject is in an exclusion period determined by a previous study
  • The patients is under judicial protection
  • The subject or their representative refused to sign the consent form
  • It proves impossible to give the subject or their representative clear information.
  • Patients with atypical degenerative parkinsonian syndrome
  • Patients with vascular, post-traumatic, metabolic, toxic or genetic parkinsonian syndrome
  • Appearance of parkinsonian syndrome prior to treatment with anti-dopamine
  • Injection of botulinum toxin into the salivary glands
  • Contra-indication on DAT-scan (unbalanced dysthyroidism, allergy, treatment with bupropion or amphetaminergics)
  • Poor oral health (polyposis, gingivostomatitis) observed during the odontologist visit
  • Patients not taking anti-psychotics with parkinsonian syndrome and normal DAT-scan

结局指标

主要结局

Compare saliva level of oligomeric alpha-synuclein between two groups of patients wth classical parkinsonian: patients with idiopathic Parkinson disease and patients with a acquired parkinsonian syndrome from anti-dopamine treatment.

时间窗: Day 0

次要结局

  • UPDRS II-III-IV score(Day 0)
  • UDysRs score(Day 0)
  • character of parkinsonian syndrome(Day 0)
  • akathisia(Day 0)
  • questionnaire on non-motor symptoms in Parkinson disease(Day 0)
  • Perform the first estimation of discriminatory capacity of saliva levels of oligomeric alpha-synuclein for diagnostic differentiation between idiopathic Parkinson disease and anti-dopamine induced acquired parkinsonian syndrome.(Day 0)
  • Compare levels of total alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein between the two groups(Day 0)
  • Perform the first estimation of discriminatory capacity of saliva levels of total oligomeric alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein for diagnostic differentiation between two groups(Day 0)
  • Creation of a biobank with remaining samples(Day 0)
  • neuro-psychological evaluation(Day 0)
  • GDS score(Day 0)
  • interogation to determine extent of motor and non-motor clinical markers to differentiate the two groups(Day 0)

研究者

发起方
Centre Hospitalier Universitaire de Nīmes
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验